denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Bleeding and Clotting, Biological therapies, Antibody Therapy, bleeding disorders, Non-Biological therapies, Workforce, Chemotherapy, platelet disorders, Diversity, Equity, and Inclusion (DEI) , drug development, Diseases, thrombocytopenias, Therapies, Study Population
Description:
Thrombocytopenia is one of the most common reasons for both inpatient and outpatient hematology consultation. Chemotherapy-induced thrombocytopenia, thrombocytopenia of chronic liver disease, and thrombocytopenia in the pregnant patient are frequently encountered and often challenging clinical situations, and optimal management in these situations can be elusive. New data for the use of thrombopoietin receptor agonists in these patients in specific situations offers opportunities for updated and modernized treatment paradigms but also raise many questions.
Dr. Hanny Al-Samkari will discuss new data for the use of the thrombopoietin receptor agonists to treat patients with chemotherapy-induced thrombocytopenia and how this data guides optimal and safe use of these agents in clinical practice.
Dr. Adam Cuker will describe the clinical consequences and optimal management of thrombocytopenia of chronic liver disease, including a discussion of the thrombopoietin receptor agonists now approved to treat these patients in the periprocedural setting.
Dr. Allyson Pishko will discuss the diagnostic challenges of thrombocytopenia in the pregnant patient as well as new data available regarding the management of pregnant patients with immune thrombocytopenia.
Dr. Hanny Al-Samkari will discuss new data for the use of the thrombopoietin receptor agonists to treat patients with chemotherapy-induced thrombocytopenia and how this data guides optimal and safe use of these agents in clinical practice.
Dr. Adam Cuker will describe the clinical consequences and optimal management of thrombocytopenia of chronic liver disease, including a discussion of the thrombopoietin receptor agonists now approved to treat these patients in the periprocedural setting.
Dr. Allyson Pishko will discuss the diagnostic challenges of thrombocytopenia in the pregnant patient as well as new data available regarding the management of pregnant patients with immune thrombocytopenia.